Back to Search Start Over

Months after an executive exodus, Exicure tells 66% of remaining staff to exit as it suspends all R&D work.

Authors :
Bayer, Max
Source :
FierceBiotech; 9/27/2022, pN.PAG-N.PAG, 1p
Publication Year :
2022

Abstract

Struggles for Exicure continue to mount, with the company announcing it would be halting all R&D work and cutting two-thirds of its team. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
EXECUTIVES
TEAMS in the workplace
NUCLEIC acids

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
159380273

Tools

Authors Abstract Subjects Details